scholarly journals Modulatory Function of Invariant Natural Killer T Cells in Systemic Lupus Erythematosus

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Yi-Ping Chuang ◽  
Chih-Hung Wang ◽  
Ning-Chi Wang ◽  
Deh-Ming Chang ◽  
Huey-Kang Sytwu
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Natural Killer ◽  
Lupus Erythematosus ◽  
Systemic Disease ◽  
Clinical Manifestations ◽  
Peripheral Tolerance ◽  
Inkt Cells ◽  
Systemic Lupus ◽  
Invariant Natural Killer ◽  
Natural Killer T

Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease with complex immunological and clinical manifestations. Multiple organ failure in SLE can be caused by immune dysfunction and deposition of autoantibodies. Studies of SLE-susceptible loci and the cellular and humoral immune responses reveal variable aberrations associated with this systemic disease. Invariant natural killer T (iNKT) cells are a unique subset of lymphocytes that control peripheral tolerance. Mounting evidence showing reductions in the proportion and activity of iNKT cells in SLE patients suggests the suppressive role of iNKT cells. Studies using murine lupus models demonstrate that iNKT cells participate in SLE progression by sensing apoptotic cells, regulating immunoglobulin production, and altering the cytokine profile upon activation. However, the dichotomy of iNKT cell actions in murine models implies complicated interactions within the body's milieu. Therefore, application of potential therapy for SLE using glycolipids to regulate iNKT cells should be undertaken cautiously.

scholarly journals Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15

PLoS ONE ◽  
2021 ◽  
Vol 16 (12) ◽  
pp. e0261727
Author(s):  
Chien-Ya Hsu ◽  
Yu-Shan Chueh ◽  
Ming-Ling Kuo ◽  
Pei-Tzu Lee ◽  
Hsiu-Shan Hsiao ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
T Cells ◽  
Natural Killer ◽  
Lupus Erythematosus ◽  
Natural Killer T Cells ◽  
Inkt Cell ◽  
Inkt Cells ◽  
Systemic Lupus ◽  
Killer T Cells ◽  
Invariant Natural Killer

CD1d-restricted invariant natural killer T cells (iNKT cells) may play an important role in the pathogenesis of systemic lupus erythematosus (SLE). Interleukin (IL)-15 is a pro-inflammatory cytokine which is over-expressed in SLE patients. In the present study, we investigated the iNKT cell expansion of mononuclear cells (MNCs) from SLE patients following 10 days’ culture with α-galactosylceramide (α-Galcer) and /or IL-15. We sought to determine the phenotypic and functional characteristics of the expanded iNKT cells compared to healthy controls and correlated with disease activity. We observed that 1. The percentages of Vα24+/Vβ11+ iNKT cells following 10-day incubation was lower in SLE groups compared to controls; 2. The percentages and absolute numbers of Vα24+/Vβ11+ iNKT cells were expanded by α-galactosylceramide (α-Galcer), and further enhanced with IL-15 in SLE patient, but the effect of IL-15 was much lower than controls; 3.IL-15 +α-Galcer expanded CD3+/CD56+ NKT-like cells from SLE patients, especially with active disease 4. The CD161+ Vα24+/Vβ11+ iNKT cells in SLE were more responsive to α-Galcer stimulation than the CD161- counterpart; 5. IL-15 decreased apoptosis of α-Galcer activated SLE iNKT cells; 6. IL-15 enhanced CD69, CD1d and CD11a expression on α-Galcer treated iNKT cells; 7. The IL-4 production of iNKT cells was decreased in SLE patients compared to controls; 8. IL-15 increased IFN-γ and IL-4 production of SLE iNKT cells; 8. IL-15 failed to augment the ability of iNKT cells to aid NK-mediated K562 cytolysis in SLE patients; 9. CD161 positivity, granzyme B and perforin expression of α-Galcer+IL-15 expanded iNKT cells correlated with C3 levels in SLE patients. Taken together, our results demonstrated numeric and functional deficiency of iNKT cells and their response to IL-15 in SLE patients. Our finding may provide insight for using adoptive iNKT cell therapy in autoimmune diseases.

scholarly journals The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand?

2021 ◽  
Vol 10 (2) ◽  
pp. 243
Author(s):  
Matteo Piga ◽  
Laurent Arnaud
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Systemic Disease ◽  
Unmet Need ◽  
Clinical Manifestations ◽  
New Drugs ◽  
Systemic Lupus ◽  
Major Step ◽  
Damage Accrual

Systemic lupus erythematosus (SLE) is an immune-mediated multi-systemic disease characterized by a wide variability of clinical manifestations and a course frequently subject to unpredictable flares. Despite significant advances in the understanding of the pathophysiology and optimization of medical care, patients with SLE still have significant mortality and carry a risk of progressive organ damage accrual and reduced health-related quality of life. New tools allow earlier classification of SLE, whereas tailored early intervention and treatment strategies targeted to clinical remission or low disease activity could offer the opportunity to reduce damage, thus improving long-term outcomes. Nevertheless, the early diagnosis of SLE is still an unmet need for many patients. Further disentangling the SLE susceptibility and complex pathogenesis will allow to identify more accurate biomarkers and implement new ways to measure disease activity. This could represent a major step forward to find new trials modalities for developing new drugs, optimizing the use of currently available therapeutics and minimizing glucocorticoids. Preventing and treating comorbidities in SLE, improving the management of hard-to-treat manifestations including management of SLE during pregnancy are among the remaining major unmet needs. This review provides insights and a research agenda for the main challenges in SLE.

scholarly journals Natural killer T cells in families of patients with systemic lupus erythematosus: Their possible role in regulation of IGG production

2006 ◽  
Vol 56 (1) ◽  
pp. 303-310 ◽  
Author(s):  
Matthew R. J. Green ◽  
Amy S. M. Kennell ◽  
Maggie J. Larche ◽  
Martin H. Seifert ◽  
David A. Isenberg ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
T Cells ◽  
Natural Killer ◽  
Lupus Erythematosus ◽  
Natural Killer T Cells ◽  
Systemic Lupus ◽  
Killer T Cells ◽  
Natural Killer T

scholarly journals Prevalence of Oral Manifestations in Systemic Lupus Erythematosus Patients Referred to Shahid Mohammadi Hospital in 2018 - 2019

2021 ◽  
Vol 13 (2) ◽  
Author(s):  
Raziyehsadat Rezvaninejad ◽  
Majid Dadmehr ◽  
Rayehehossadat Rezvaninejad
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Disease ◽  
Clinical Manifestations ◽  
Dorsal Surface ◽  
Oral Manifestations ◽  
Systemic Lupus ◽  
Cross Sectional ◽  
Local Skin ◽  
Bandar Abbas

Background: The oral mucosa is damaged in a significant percentage of patients with lupus, with the main oral lesions being ulcers, erythematous lesions, and discoid lesions. The prevalence of these lesions is estimated to vary from 9% to 45% in systemic disease and 3% to 20% in local skin disease. Objectives: One of the symptoms of lupus is its oral manifestations. Therefore, we decided to conduct a study to investigate the prevalence of oral manifestations in lupus patients referred to Shahid Mohammadi Hospital in Bandar Abbas. Methods: In this descriptive cross-sectional study, the recorded information of patients with lupus referred to Shahid Mohammadi Hospital in Bandar Abbas from 2018 to 2019 was reviewed. All enrolled patients met the American College of Rheumatology criteria for classifying lupus. Recorded information, including demographic characteristics and various clinical manifestations, was recorded after examining the patients. Data were analyzed using SPSS-22 software. Results: A total of 76 patients were studied. Of them, 23 (30.2%) were males, and 53 (69.8%) were females. The mean age of the participants was 6.1 ± 42.9. The most common site of oral lesion in the participants was the lip area (36 patients), followed by buccal mucosa (22 patients), hard palate (14 patients), and dorsal surface of the tongue (four patients). The majority of the clinical manifestations of the lesion were wounds (36 individuals), followed by white and red lesions (20 patients), non-cleansing white lesions (12 patients), and red lesions (eight individuals). Conclusions: Oral symptoms are usually the first signs of this disease. For this reason, dentists have an important role to play in diagnosing emerging autoimmune diseases. Ulcers are the most prevalent clinical manifestations, according to this study, and the lips are the most prevalent location. As a result, in patients with systemic lupus erythematosus, these two findings should be given greater importance than others.

scholarly journals Immunoregulation of NKT Cells in Systemic Lupus Erythematosus

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Junwei Chen ◽  
Meng Wu ◽  
Jing Wang ◽  
Xiaofeng Li
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Clinical Manifestations ◽  
Nkt Cells ◽  
Regulatory Role ◽  
Inkt Cells ◽  
Systemic Lupus ◽  
Therapy Strategy ◽  
Autoreactive Antibodies ◽  
Innate Lymphocytes

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with different variety of clinical manifestations. Natural killer T (NKT) cells are innate lymphocytes that play a regulatory role during broad range of immune responses. A number of studies demonstrated that the quantity and quality of invariant NKT (iNKT) cells showed marked defects in SLE patients in comparison to healthy controls. This finding suggests that iNKT cells may play a regulatory role in the occurrence and development of this disease. In this review, we mainly summarized the most recent findings about the behavior of NKT cells in SLE patients and mouse models, as well as how NKT cells affect the proportion of T helper cells and the production of autoreactive antibodies in the progress of SLE. This will help people better understand the role of NKT cells in the development of SLE and improve the therapy strategy.

Sign in / Sign up

Export Citation Format

Share Document